How IGFBP-3 improves cancer cell responsiveness to DNA-damaging therapies

IGFBP-3 如何改善癌细胞对 DNA 损伤疗法的反应

• 批准号: DP0984232
• 负责人: Prof Robert Baxter
• 金额: $ 33.28万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: Discovery Projects
• 财政年份: 2009
• 资助国家: 澳大利亚
• 起止时间: 2009-01-21 至 2013-01-21
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/DP0984232
• 关键词: How; IGFBP; improves; cancer; cell

A protein called IGFBP-3 can modulate the way cancer cells respond to treatments such as radiotherapy and certain chemotherapy drugs. These therapies, which act by damaging cells' DNA, play an important role in the treatment of many cancers, but their effectiveness is limited by the ability of cells to oppose the treatment by repairing damaged DNA. This project aims to discover how IGFBP-3 acts to change cancer cells' response to treatment, using breast cancer cells growing in culture as a model system. This work has the potential to lead to improvements in the treatment of cancer patients by increasing our understanding of what happens when cancer cells are exposed to radio- or chemotherapy.

一种名为IGFBP-3的蛋白质可以调节癌细胞对放疗和某些化疗药物等治疗的反应。这些疗法通过破坏细胞的DNA发挥作用，在许多癌症的治疗中发挥着重要作用，但它们的有效性受到细胞通过修复受损DNA来对抗治疗的能力的限制。该项目旨在发现IGFBP-3如何改变癌细胞对治疗的反应，使用培养的乳腺癌细胞作为模型系统。这项工作有可能通过增加我们对癌细胞暴露于放射或化疗时会发生什么的理解，来改善癌症患者的治疗。